Alumis reports Q1 2026 net loss $93.1M, cash and marketable securities $569.5M
1 min read
Alumis reported a net loss of $93.1 million for the quarter ended March 31, 2026, and held $569.5 million in cash, cash equivalents and marketable securities as of the period end. Revenue for Q1 2026 was $1.7 million, driven by collaboration revenue, versus license revenue of $17.4 million in the prior-year quarter. The company reiterated plans to submit an NDA for envudeucitinib in 4Q 2026 and expects SLE Phase 2b topline data in 3Q 2026.
Financial Highlights
- Total revenue: $1.7 million for the three months ended March 31, 2026 (collaboration revenue).
- Net loss: $93.1 million for the three months ended March 31, 2026.
- Research and development expenses: $81.5 million for Q1 2026.
- General and administrative expenses: $18.6 million for Q1 2026.
- Cash, cash equivalents and marketable securities: $569.5 million as of March 31, 2026.
Business Highlights
- Envudeucitinib Phase 3 ONWARD1 and ONWARD2 data presented as a late-breaking oral presentation at AAD 2026, showing robust PASI responses by Week 16 with continued improvement by Week 24 (PASI 90: 68.0% and 62.1%; PASI 100: 41.0% and 39.5%).
- Patient-reported improvements in quality of life and itch relief observed earlier than PASI 90, and clear/almost clear scalp psoriasis seen in >30% by Week 4 and ~75% by Week 24 (baseline ss-PGA ≥3).
- NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis remains on track for 4Q 2026; potentially pivotal Phase 2b SLE topline data anticipated in 3Q 2026.
- Company published a narrative review characterizing envudeucitinib as a next-generation oral allosteric TYK2 inhibitor and held a KOL event with dermatology experts following AAD presentation.
- Alumis completed a strategic review of the lonigutamab program and is exploring strategic alternatives for that asset; plans to present a unified TYK2 franchise strategy and evaluate additional indications in 2Q 2026.
Original SEC Filing: ALUMIS INC. [ ALMS ] - 8-K - May. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.